Fibromuscular Dysplasia Treatment Market Size, Share and Global Trend By Drug Class (Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Diuretics, Calcium channel blockers, Beta-blockers, Others), By Distribution Channel (Hospitals pharmacies, Retail pharmacies, Online pharmacies) and Regional Forecast, 2024-2032

Fibromuscular dysplasia (FMD) is a disease characterized by abnormal growth of the cells in the walls of the arteries, which thickens, narrows and even enlarges the arteries making the blood flow difficult. Fibromuscular dysplasia (FMD) often affects the renal arteries, carotid arteries, abdominal arteries and arteries of arms and legs.

The cause of fibromuscular dysplasia (FMD) disease is unknown but some of the factors considered for the cause are genetic, change in hormones and lack of oxygen supply to the arteries. At present, there is no cure for fibromuscular dysplasia. Current treatments for FMD include surgical revascularization, percutaneous transluminal angioplasty (PTA), and drugs like angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers among others.

The rise in the prevalence of hypertension among the global population and sedentary lifestyle owing to the rising prevalence of fibromuscular dysplasia. Increasing prevalence of smoking is leading to a higher risk of the fibromuscular dysplasia acroos the globe. The Centers for Disease Control and Prevention stated that in 14% of the adults in the U.S were smokers in the year 2017. This is one major factor expected to present a large patient pool requiring treatment and will drive the growth of the global fibromuscular dysplasia (FMD) treatment market during the forecast period.

However, side effects of the treatment to the patients, lack of robust healthcare infrastructure in emerging countries and presence generic drugs in the market are some of the major restraining factors of the global fibromuscular dysplasia (FMD) treatment market.

Key Players Covered

Some of the major companies that are present in the global fibromuscular dysplasia (FMD) treatment market are ALVOGEN, Aspen Surgical Products, Inc., AstraZeneca, B. Braun Melsungen AG, Bayer Healthcare Pharmaceuticals Inc., Becton, Dickinson and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd, Ethicon, Inc., Merck, Novartis, Pfizer, Sanofi-Aventis, Smith & Nephew plc; Medtronic, Stryker Corporation, and Watson Pharma Private Limited.

SEGMENTATION

Among drug class segmentation angiotensin-converting enzyme (ACE) inhibitors are projected to dominate the global fibromuscular dysplasia treatment market owing to greater efficacy offered by the drug.

Key Insights

• Epidemiology overview of fibromuscular dysplasia


• Overview of the regulatory scenario for key countries


• Key Industry Developments - Mergers, Acquisitions and Partnerships

Regional Analysis

The global fibromuscular dysplasia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is estimated to account for the largest share in the global fibromuscular dysplasia (FMD) treatment market in 2018, owing to the increasing prevalence of fibromuscular dysplasia (FMD), rising prevalence of smoking among the general population, and rising investments in R&D to understand the progression of fibromuscular dysplasia. Asia Pacific is expected to gain market share from 2019-2026, owing to a higher prevalence of hypertension and smoking, increasing per capita healthcare expenditure leading to higher demand for new and advanced treatments for fibromuscular dysplasia (FMD). Additionally, the fibromuscular dysplasia treatment market is estimated to grow positively in this region owing to the rise in government initiatives taken towards awareness about the symptoms of the disease.

Key Industry Developments

• In January 2019, the first international consensus on the diagnosis and management of fibromuscular dysplasia was published online in the Journal of Hypertension and Vascular Medicine.


• In November 2017, the Mayo Clinic initiated a Phase 1 clinical trial to study the use of ultrasonography, shear wave elastography, strain imaging, and 3-D volume ultrasonography in identifying arterial elastic characteristics in patients suffering from fibromuscular dysplasia.